These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 26110843)
1. Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. Gnad F; Doll S; Manning G; Arnott D; Zhang Z BMC Genomics; 2015; 16 Suppl 8(Suppl 8):S5. PubMed ID: 26110843 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations. Barsotti AM; Ryskin M; Rollins RA Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265 [No Abstract] [Full Text] [Related]
3. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712 [TBL] [Abstract][Full Text] [Related]
4. EZH2 as a potential target in cancer therapy. McCabe MT; Creasy CL Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487 [TBL] [Abstract][Full Text] [Related]
5. Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas. Purkait S; Sharma V; Kumar A; Pathak P; Mallick S; Jha P; Sharma MC; Suri V; Julka PK; Suri A; Sharma BS; Sarkar C Exp Mol Pathol; 2016 Apr; 100(2):312-20. PubMed ID: 26892683 [TBL] [Abstract][Full Text] [Related]
6. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398 [TBL] [Abstract][Full Text] [Related]
7. Methyltransferase expression and tumor suppressor gene methylation in sporadic and familial colorectal cancer. Joensuu EI; Nieminen TT; Lotsari JE; Pavicic W; Abdel-Rahman WM; Peltomäki P Genes Chromosomes Cancer; 2015 Dec; 54(12):776-87. PubMed ID: 26305882 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303 [TBL] [Abstract][Full Text] [Related]
9. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma. Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Sponziello M; Durante C; Boichard A; Dima M; Puppin C; Verrienti A; Tamburrano G; Di Rocco G; Redler A; Lacroix L; Bidart JM; Schlumberger M; Damante G; Russo D; Filetti S Mol Cell Endocrinol; 2014 Jul; 392(1-2):8-13. PubMed ID: 24813658 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Tsang DP; Cheng AS J Gastroenterol Hepatol; 2011 Jan; 26(1):19-27. PubMed ID: 21175789 [TBL] [Abstract][Full Text] [Related]
12. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001 [TBL] [Abstract][Full Text] [Related]
13. EZH2 in Bladder Cancer, a Promising Therapeutic Target. Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594 [TBL] [Abstract][Full Text] [Related]
14. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis. Zhang Y; Tong T Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199 [TBL] [Abstract][Full Text] [Related]
15. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Simon JA; Lange CA Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033 [TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature. Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic modification in gliomas: role of the histone methyltransferase EZH2. Bian EB; Li J; He XJ; Zong G; Jiang T; Li J; Zhao B Expert Opin Ther Targets; 2014 Oct; 18(10):1197-206. PubMed ID: 25046371 [TBL] [Abstract][Full Text] [Related]
18. Targeting histone methyltransferase EZH2 as cancer treatment. Kondo Y J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367 [TBL] [Abstract][Full Text] [Related]
19. Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation. Qi Y; Zhang X; Kang Y; Wu J; Chen J; Li H; Guo Y; Liu B; Shao Z; Zhao X Mol Biosyst; 2015 Jul; 11(7):1980-6. PubMed ID: 25947258 [TBL] [Abstract][Full Text] [Related]
20. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Benetatos L; Voulgaris E; Vartholomatos G; Hatzimichael E Int J Cancer; 2013 Jul; 133(2):267-74. PubMed ID: 23001607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]